Bonjour à tous,
Vous trouverez ci-dessous les titres des publications des membres du réseau ENDOCAN TUTHYREF.
Félicitations aux auteurs!

Retrouvez les publications dans :   Espace membre

2024

1. Neyrand, Sophie; Trecourt, Alexis; Lopez, Jonathan; Just, Pierre Alexandre; Descotes, Françoise; Borson-Chazot, Françoise; Ray-Coquard, Isabelle; Decaussin-Petrucci, Myriam; Devouassoux-Shisheboran, Mojgan (2024) Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii. In : Histopathology, vol. 84, n° 2, p. 291–300. DOI: 10.1111/his.15052.

Résulats sur la période de Janvier à Mars 2024:

1. Aksoy YA, Xu B, Viswanathan K, Ahadi MS, Al Ghuzlan A, Alzumaili B, Bani MA, Barletta JA, Chau N, Chou A, Clarkson A, Clifton-Bligh RJ, De Leo A, Dogan S, Ganly I, Ghossein R, Gild ML, Glover AR, Hadoux J, Lamartina L, Lubin DJ, Magliocca K, Najdawi F, Nigam A, Papachristos A, Repaci A, Robinson BG, Sheen A, Shi Q, Sidhu SB, Sioson L, Solaroli E, Sywak MS, Tallini G, Tsang V, Turchini J, Untch BR, Gill AJ, Fuchs TL. Novel prognostic nomogram for predicting recurrence-free survival in medullary thyroid carcinoma. Histopathology. 2024 Jan 22. doi: 10.1111/his.15141. Epub ahead of print. PMID: 38253940.
   
   
2. Attanasio-et-al-2024-patients-persistent-symptoms
   Attanasio R, Žarković M, Papini E, Nagy EV, Negro R, Perros P, Akarsu E, Alevizaki M, Ayvaz G, Bednarczuk T, Beleslin B, Berta E, Bodor M, Borissova AM, Boyanov M, Buffet C, Burlacu MC, Ciric J, Díez JJ, Dobnig H, Fadeyev VV, Field BC, Fliers E, Führer D, Galofré JC, Hakala T, Jiskra J, Kopp PA, Krebs M, Kršek M, Kuzma M, Lantz M, Lazúrová I, Leenhardt L, Luchytskiy V, Marques Puga F, McGowan A, Metso S, Moran C, Morgunova T, Niculescu DA, Perić B, Planck T, Poiana C, Robenshtok E, Rosselet PO, Ruchala M, Ryom Riis K, Shepelkevich A, Tronko MD, Unuane D, Vardarli I, Visser WE, Vryonidou A, Younes YR, Hegedus L. Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists: The "THESIS"* collaboration (*Treatment of Hypothyroidism in Europe by Specialists, an International Survey). Thyroid. 2024 Feb 18. doi: 10.1089/thy.2023.0580. Epub ahead of print. PMID: 38368541.
   
   
3. de la Fouchardière C, Fugazzola L, Locati LD, Alvarez CV, Peeters RP, Camacho P, Simon IM, Jarząb B, Netea-Maier R. Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe. 2024 Mar;83(3):585-593. doi: 10.1007/s12020-023-03610-5. Epub 2023 Nov 25. PMID: 38001324; PMCID: PMC10901911.
   
   
4. Decaussin-Petrucci M, Cochand Priollet B, Leteurtre E, Albarel F, Borson- Chazot F. Consensus SFE-AFCE-SFMN 2022 sur la prise en charge des nodules thyroïdiens : intérêt et place de la cytologie thyroïdienne [SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules: Interest and place of thyroid cytology]. Ann Pathol. 2024 Feb;44(1):20-29. French. doi: 10.1016/j.annpat.2023.10.002. Epub 2023 Dec 12. PMID: 38092572.
5. do Prado Padovani R, Duarte FB, Nascimento C. Current practice in intermediate risk differentiated thyroid cancer - a review. Rev Endocr Metab Disord. 2024 Feb;25(1):95-108. doi: 10.1007/s11154-023-09852-y. Epub 2023 Nov 23. PMID: 37995023.
   
   
6. El Fakiri M, Ayada N, Müller M, Hvass L, Gamzov TH, Clausen AS, Geis NM, Steinacker N, Hansson E, Lindegren S, Aneheim E, Jensen H, Eder AC, Jensen AI, Poulie CBM, Kjaer A, Eder M, Herth MM. Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted α-Therapy of Prostate Cancer. J Nucl Med. 2024 Feb 29:jnumed.123.267043. doi: 10.2967/jnumed.123.267043. Epub ahead of print. PMID: 38423784.
   
   
7. Fages V, Jannin A, Maanaoui M, Glowacki F, Do Cao C. Proteinuria reduction with SGLT2 inhibitors in a patient treated with tyrosine kinase inhibitor lenvatinib. J Nephrol. 2024 Jan;37(1):187-189. doi: 10.1007/s40620-023-01701-0. Epub 2023 Jul 7. PMID: 37418091.
   
   
8. Frey S, Caillard C, Mahot P, Drui D, Mirallié E. Amiodarone-induced thyrotoxicosis: Should surgery be considered? Ann Endocrinol (Paris). 2024 Jan 19:S0003-4266(24)00006-4. doi: 10.1016/j.ando.2024.01.006. Epub ahead of print. PMID: 38246417.
   
   
9. Guerlain J, Breuskin I, Abbaci M, Lamartina L, Hadoux J, Baudin E, Al Ghuzlan A, Moog S, Marhic A, Villard A, Obongo R, Hartl DM. Intraoperative Parathyroid Gland Identification Using Autofluorescence Imaging in Thyroid Cancer Surgery with Central Neck Dissection: Impact on Post-Operative Hypocalcemia. Cancers (Basel). 2023 Dec 29;16(1):182. doi: 10.3390/cancers16010182. PMID: 38201609; PMCID: PMC10778041.
10. Haissaguerre M, Lamartina L, Caron P. Key data from the 2023 European Thyroid Association annual meeting: De-escalation strategy in diagnosis and the treatment of differentiated thyroid carcinoma: Update after the 2023 ETA congress. Ann Endocrinol (Paris). 2024 Jan 17:S0003-4266(24)00003-9. doi: 10.1016/j.ando.2024.01.003. Epub ahead of print. PMID: 38336563.
    
    
11. Lacoste-Collin L, Decaussin-Petrucci M, Buffet C. Les tests moléculaires et autres techniques ancillaires en cytologie thyroïdienne selon Bethesda 2023 [Molecular and other ancillary tests proposed by The Bethesda system for reporting thyroid cytopathology 2023]. Ann Pathol. 2024 Feb;44(1):36-46. French. doi: 10.1016/j.annpat.2023.10.004. Epub 2023 Nov 10. PMID: 37953129.
    
    
12. Lasolle H, Schiavo A, Tourneur A, Gillotay P, de Faria da Fonseca B, Ceolin L, Monestier O, Aganahi B, Chomette L, Kizys MML, Haenebalcke L, Pieters T, Goossens S, Haigh J, Detours V, Maia ALS, Costagliola S, Romitti M. Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids. Oncogene. 2024 Jan;43(3):155-170. doi: 10.1038/s41388-023-02889-y. Epub 2023 Nov 20. PMID: 37985676; PMCID: PMC10786723.
    
    
13. Latgé A, Krim M, Vija L, Ysebaert L, Zerdoud S. Diffuse Bone Uptake of 131 I and Effect on Blood Counts in a Patient With Papillary Thyroid Carcinoma and Chronic Lymphocytic Leukemia. Clin Nucl Med. 2024 Apr 1;49(4):340-341. doi: 10.1097/RLU.0000000000005119. Epub 2024 Feb 9. PMID: 38377372.
    
    
14. Neyrand S, Trecourt A, Lopez J, Just PA, Descotes F, Borson-Chazot F, Ray-Coquard I, Decaussin-Petrucci M, Devouassoux-Shisheboran M. Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii. Histopathology. 2024 Jan;84(2):291-300. doi: 10.1111/his.15052. Epub 2023 Sep 28. PMID: 37771077.
    
    
15. Puga FM, Al Ghuzlan A, Hartl DM, Bani MA, Moog S, Pani F, Breuskin I, Guerlain J, Faron M, Denadreis D, Baudin E, Hadoux J, Lamartina L. Impact of lymphovascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study. Endocrine. 2024 Jan;83(1):150-159. doi: 10.1007/s12020-023-03475-8. Epub 2023 Aug 28. PMID: 37639174; PMCID: PMC10805903.
    
    
16. Rao KN, Randolph GW, Lopez F, Zafereo M, Coca-Pelaz A, Piazza C, Dange P, Rodrigo JP, Stenman G, de Keizer B, Nixon I, Sinha S, Leboulleux S, Mäkitie AA, Agaimy A, Thompson L, Ferlito A; This paper was written by members and invitees of the International Head and Neck Scientific Group. Assessment of the risk of malignancy in Bethesda III thyroid nodules: a comprehensive review. Endocrine. 2024 Feb 28. doi: 10.1007/s12020-024-03737-z. Epub ahead of print. PMID: 38416380.
    
    
17. Raymond P, Klein M, Borson-Chazot F. Summary and update on the management of differentiated thyroid cancer in 2023. Ann Endocrinol (Paris). 2024 Feb 3:S0003-4266(24)00012-X. doi: 10.1016/j.ando.2023.11.007. Epub ahead of print. PMID: 38316254.
    
    
18. Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 Jan;34(1):26-40. doi: 10.1089/thy.2023.0363. PMID: 38009200.
    
    
19. Theodon H, Guillerm E, Wassermann J, Deniziaut G, Jaffrelot L, Denis JA, Chereau N, Bigorgne C, Potonnier W, Coulet F, Leenhardt L, Buffet C. Next- Generation-Sequencing on fine needle aspirates in neck recurrence of thyroid cancers. Eur Thyroid J. 2024 Jan 1;13(1):e230164. doi: 10.1530/ETJ-23-0164. Epub ahead of print. PMID: 38236745; PMCID: PMC10895307.
    
    
20. Xu B, Viswanathan K, Ahadi MS, Ahmadi S, Alzumaili B, Bani MA, Baudin E, Behrman DB, Capelletti M, Chau NG, Chiarucci F, Chou A, Clifton-Bligh R, Coluccelli S, de Biase D, De Leo A, Dogan S, Fagin JA, Fuchs TL, Glover AR, Hadoux J, Lacroix L, Lamartina L, Lubin DJ, Luxford C, Magliocca K, Maloberti T, Mohanty AS, Najdawi F, Nigam A, Papachristos AJ, Repaci A, Robinson B, Scoazec JY, Shi Q, Sidhu S, Solaroli E, Sywak M, Tuttle RM, Untch B, Barletta JA, Al Ghuzlan A, Gill AJ, Ghossein R, Tallini G, Ganly I. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study. Thyroid. 2024 Feb;34(2):167-176. doi: 10.1089/thy.2023.0279. Epub 2023 Nov 7. PMID: 37842841; PMCID: PMC10884546.
    

Résultat de la veille TUTHYREF du 2ème trimestre 2024

1. Brose MS, Capdevila J, Elisei R, Bastholt L, Führer-Sakel D, Leboulleux S, Sugitani I, Taylor MH, Wang Z, Wirth LJ, Worden FP, Bernard J, Caferra P, Colzani RM, Liu S, Schlumberger M. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocr Relat Cancer. 2024 Jun 1:ERC-23-0354. doi: 10.1530/ERC-23-0354. Epub ahead of print. PMID: 38828895.

2. Caillé S, Debreuve-Theresette A, Vitellius G, Deguelte S, La Manna L, Zalzali M. Medullary Thyroid Cancer: Epidemiology and Characteristics According to Data From the Marne-Ardennes Register 1975-2018. J Endocr Soc. 2024 May 13;8(6):bvae084. doi: 10.1210/jendso/bvae084. PMID: 38745826; PMCID: PMC11091837.

3. Demeulemeester R, Grosclaude P, Grunenwald S, Saint-Pierre P, Savy N, Costa N. Identification and Economic Evaluation of Differentiated Thyroid Cancer Care Consumption Patterns Using Sequence Analysis. Int J Public Health. 2024 Apr 19;69:1606664. doi: 10.3389/ijph.2024.1606664. PMID: 38707870; PMCID: PMC11066236.

4. Kuczma P, Radu DM, Onorati I, Ghander C, Buffet C, Leenhardt L, Simon JM, Vicaut E, Trésallet C, Martinod E. Tracheal reconstruction using stented aortic matrices in advanced thyroid cancer. Br J Surg. 2024 Jun 12;111(6):znae134. doi: 10.1093/bjs/znae134. PMID: 38875135.

5. Legrand A, Bernier MO, Bressand A, Buffet C, Mandin C, Menegaux F, Soret M, Broggio D, Bassinet C, Huet C, Leenhardt L, Lussey-Lepoutre C, Baudin C. Health- related quality of life and radioiodine therapy in thyroid cancer patients: a before-and-after study. Qual Life Res. 2024 Jun 22. doi: 10.1007/s11136-024-03721-0. Epub ahead of print. PMID: 38907832.

6. Marchand JG, Ghander C, Bienvenu-Perrard M, Rouxel A, Buffet C, Russ G. Normal Parathyroid Glands Are Most Often Seen on Neck Ultrasound. Acad Radiol. 2024 May 21:S1076-6332(24)00191-0. doi: 10.1016/j.acra.2024.03.026. Epub ahead of print. PMID: 38777720.

7. Raymond P, Klein M, Borson-Chazot F. Summary and update on the management of differentiated thyroid cancer in 2023. Ann Endocrinol (Paris). 2024 Apr;85(2):110-117. doi: 10.1016/j.ando.2023.11.007. Epub 2024 Feb 3. PMID: 38316254.

8. Schubert L, Mbekwe-Yepnang AM, Wassermann J, Braik-Djellas Y, Jaffrelot L, Pani F, Deniziaut G, Lussey-Lepoutre C, Chereau N, Leenhardt L, Bernier MO, Buffet C. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status. J Endocrinol Invest. 2024 Jun;47(6):1573-1581. doi: 10.1007/s40618-024-02352-z. Epub 2024 Apr 5. PMID: 38578580; PMCID: PMC11143047.